Study Phase 3

A clinical evaluation of the effect of maintaining haemoglobin levels with weekly EPREX®/ERYPO® (Epoetin alfa) in subjects with lymphoid malignancies (Hodgkin’s Disease, Non-Hodgkin’s Lymphoma, Chronic Lymphocytic Leukemia and Multiple Myeloma) undergoing chemotherapy

  • PDF icon for CSR Summary CSR Summary Not Available
  • Globe symbol for NCT Number NCT Number Not Available
  • Notebook for Primary Citation Primary Citation Not Available
  • Spreadsheet for Data Specification Data Specification Not Available

Trial Information

Generic NameEpoetin alfaProduct NamePROCRIT®Therapeutic AreaBlood and Lymph ConditionsEnrollment1000% FemaleN/A% WhiteN/A
Product ClassHematologic AgentsSponsor Protocol NumberOBE/EPO-INT-02Data PartnerJohnson & JohnsonCondition StudiedAnemiaMean/Median Age (Years)58.9

Supporting Documentation

  • Collected Datasets Available
Additional Information

Three narratives are available upon data request approval for Study OBE-EPO-INT-02: Subjects With Disease Progression, Subjects Who Died, and Subjects with Thrombovascular Events.


Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.